UNSPSC 51431600: Antihypertensive amines

Antihypertensive drugs made from a group of compounds derived from ammonia by substituting organic radicals for the hydrogens.

UNSPSC 51431600 Antihypertensive amines is a Class code under which state and local governments procure emergency medications and pharmaceutical products for healthcare delivery, including injectable cardiovascular agents used in advanced life support protocols. The scope of work encompasses supply of specific medication formulations with defined expiration and shelf-life requirements, compliance with FDA and OSHA standards, and rapid delivery timelines. Issuing bodies include municipal fire rescue departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances spanning multiple states and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). The code sees activity from cities, state agencies, and regional cooperative vehicles rather than a single dominant purchaser, with issuers seeking competitive pricing and vendor flexibility around wholesaler relationships, manufacturing compliance, and direct-to-manufacturer or conventional distribution channels.

Recent solicitation activity spans the Southeast and upper Midwest. Tampa, Florida's Purchasing Department posted an IFB (Solicitation 26P00188) on April 24, 2026 for Advanced Life Support Medications—Labetalol HCI, Epinephrine, Adenosine, and Diltiazem—with a response deadline of April 8, 2026 and estimated contract value of $40,000, open to vendors with a 5 percent SLBE bid discount available. Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs without rebates, aimed at informing future RFP development. The Minnesota Multistate Cooperative Purchasing Alliance posted an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness set for July 1, 2026 and performance penalties of $200 to $1,500 per violation. Vendors must maintain cGMP certification, DSCSA compliance, and insurance coverage of $5 million general liability plus $2 million network security and professional liability; pricing evaluation weights price competitiveness at 75 percent.